Department of Animal Biology and Conservation Science, School of Biological Sciences, College of Basic and Allied Sciences, University of Ghana, Accra, Ghana.
Department of Epidemiology, Noguchi Memorial Institute for Medical Research, College of Health Sciences, University of Ghana, Accra, Ghana.
Parasit Vectors. 2018 Mar 12;11(1):175. doi: 10.1186/s13071-018-2762-3.
Plasmodium falciparum delayed clearance with the use of artemisinin-based combination therapy (ACTs) has been reported in some African countries. Single nucleotide polymorphisms (SNPs) in two genes, P. falciparum adaptor protein complex 2 mu subunit (pfap2mu) and ubiquitin specific protease 1 (pfubp1), have been linked to delayed clearance with ACT use in Kenya and recurrent imported malaria in Britain. With over 12 years of ACT use in Ghana, this study investigated the prevalence of SNPs in the pfap2mu and pfubp1 in Ghanaian clinical P. falciparum isolates to provide baseline data for antimalarial drug resistance surveillance in the country.
Filter paper blood blots collected in 2015-2016 from children aged below 9 years presenting with uncomplicated malaria at hospitals in three sentinel sites Begoro, Cape Coast and Navrongo were used. Parasite DNA was extracted from 120 samples followed by nested polymerase chain reaction (nPCR). Sanger sequencing was performed to detect and identify SNPs in pfap2mu and pfubp1 genes.
In all, 11.1% (9/81) of the isolates carried the wildtype genotypes for both genes. A total of 164 pfap2mu mutations were detected in 67 isolates whilst 271 pfubp1 mutations were observed in 72 isolates. The majority of the mutations were non-synonymous (NS): 78% (128/164) for pfap2mu and 92.3% (250/271) for pfubp1. Five unique samples had a total of 215 pfap2mu SNPs, ranging between 15 and 63 SNPs per sample. Genotypes reportedly associated with ART resistance detected in this study included pfap2mu S160N (7.4%, 6/81) and pfubp1 E1528D (7.4%, 6/81) as well as D1525E (4.9%, 4/81). There was no significant difference in the prevalence of the SNPs between the three ecologically distinct study sites (pfap2mu: χ = 6.905, df = 2, P = 0.546; pfubp1: χ = 4.883, df = 2, P = 0.769).
The detection of pfap2mu and pfubp1 genotypes associated with ACT delayed parasite clearance is evidence of gradual nascent emergence of resistance in Ghana. The results will serve as baseline data for surveillance and the selection of the genotypes with drug pressure over time. The pfap2mu S160N, pfubp1 E1528D and D1525E must be monitored in Ghanaian isolates in ACT susceptibility studies, especially when cure rates of ACTs, particularly AL, is less than 100%.
在一些非洲国家,已报道青蒿素为基础的联合疗法(ACTs)使用后疟原虫清除延迟。在肯尼亚,疟原虫适应蛋白复合物 2 微亚基(pfap2mu)和泛素特异性蛋白酶 1(pfubp1)的两个基因中的单核苷酸多态性(SNPs)与 ACT 使用后清除延迟和英国复发性输入性疟疾有关。加纳使用 ACT 已有 12 多年,本研究调查了加纳临床疟原虫分离株中 pfap2mu 和 pfubp1 基因的 SNPs 流行情况,为该国抗疟药耐药性监测提供基线数据。
使用 2015-2016 年在三个哨点Begoro、Cape Coast 和 Navrongo 的医院就诊的 9 岁以下患有单纯性疟疾的儿童的滤纸血斑采集了血液样本。从 120 个样本中提取寄生虫 DNA,然后进行巢式聚合酶链反应(nPCR)。对 pfap2mu 和 pfubp1 基因进行 Sanger 测序,以检测和鉴定 SNPs。
总共 81 个分离株中,有 11.1%(9/81)的分离株两个基因均为野生型基因型。在 67 个分离株中检测到 164 个 pfap2mu 突变,在 72 个分离株中观察到 271 个 pfubp1 突变。大多数突变是非同义的(NS):pfap2mu 为 78%(128/164),pfubp1 为 92.3%(250/271)。五个独特的样本共有 215 个 pfap2mu SNPs,每个样本的数量在 15 到 63 个之间。本研究中检测到的与 ART 耐药相关的基因型包括 pfap2mu S160N(7.4%,6/81)和 pfubp1 E1528D(7.4%,6/81)以及 D1525E(4.9%,4/81)。在三个生态区具有不同特征的研究地点之间,这些 SNPs 的流行率没有显著差异(pfap2mu:χ = 6.905,df = 2,P = 0.546;pfubp1:χ = 4.883,df = 2,P = 0.769)。
pfap2mu 和 pfubp1 基因型与 ACT 寄生虫清除延迟相关的检测表明,加纳的耐药性正在逐渐出现。这些结果将作为监测的基线数据,并随着时间的推移选择具有药物压力的基因型。在加纳 ACT 敏感性研究中,必须监测 pfap2mu S160N、pfubp1 E1528D 和 D1525E 基因型,特别是在 ACT 治愈率低于 100%时。